Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CERTOLIZUMAB PEGOL Cause Muscular weakness? 1,220 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 1,220 reports of Muscular weakness have been filed in association with CERTOLIZUMAB PEGOL (Cimzia). This represents 1.2% of all adverse event reports for CERTOLIZUMAB PEGOL.

1,220
Reports of Muscular weakness with CERTOLIZUMAB PEGOL
1.2%
of all CERTOLIZUMAB PEGOL reports
731
Deaths
841
Hospitalizations

How Dangerous Is Muscular weakness From CERTOLIZUMAB PEGOL?

Of the 1,220 reports, 731 (59.9%) resulted in death, 841 (68.9%) required hospitalization, and 718 (58.9%) were considered life-threatening.

Is Muscular weakness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CERTOLIZUMAB PEGOL. However, 1,220 reports have been filed with the FAERS database.

What Other Side Effects Does CERTOLIZUMAB PEGOL Cause?

Drug ineffective (23,838) Rheumatoid arthritis (17,782) Pain (13,929) Fatigue (11,438) Off label use (10,281) Rash (9,663) Alopecia (9,111) Maternal exposure during pregnancy (9,013) Arthralgia (8,993) Abdominal discomfort (8,615)

What Other Drugs Cause Muscular weakness?

ADALIMUMAB (3,605) METHOTREXATE (2,813) RITUXIMAB (2,621) ATORVASTATIN (2,494) PREDNISONE (2,236) ETANERCEPT (2,207) DALFAMPRIDINE (1,916) TOCILIZUMAB (1,790) FINGOLIMOD (1,769) SECUKINUMAB (1,747)

Which CERTOLIZUMAB PEGOL Alternatives Have Lower Muscular weakness Risk?

CERTOLIZUMAB PEGOL vs CERTOPARIN CERTOLIZUMAB PEGOL vs CETIRIZINE CERTOLIZUMAB PEGOL vs CETIRIZINE\PSEUDOEPHEDRINE CERTOLIZUMAB PEGOL vs CETRIMIDE CERTOLIZUMAB PEGOL vs CETRORELIX

Related Pages

CERTOLIZUMAB PEGOL Full Profile All Muscular weakness Reports All Drugs Causing Muscular weakness CERTOLIZUMAB PEGOL Demographics